Download full-text PDF |
Source |
---|
Antimicrob Agents Chemother
December 2024
GSK, Durham, North Carolina, USA.
Int J Emerg Med
July 2024
Advanced Critical Care Center, Gifu University Hospital, 1-1 Yanagido, Gifu-Shi, Gifu, 501-1194, Japan.
Br J Clin Pharmacol
September 2024
Laboratorios Farmacéuticos ROVI, S.A., Madrid, Spain.
Aims: The aims of this study were to develop a population pharmacokinetic (PK) model for risperidone ISM® and to investigate the relationships between active moiety exposure, as described by apparent clearance (CL), and several covariates using all data from five clinical studies.
Methods: A population PK model was developed using active moiety concentrations from a study in healthy volunteers and two studies in patients with schizophrenia. Data from a comparative bioavailability study in medically stable patients and a Phase III study in patients with acute exacerbation of schizophrenia were then incorporated, using empirical Bayesian feedback and model refinement in NONMEM.
Local Reg Anesth
April 2024
Health Unit, International Committee of the Red Cross, Geneva, Switzerland.
Trauma Case Rep
June 2024
2001 Vail Ave, Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute, Charlotte, NC 28207, USA.
Background: Gluteal Compartment Syndrome (GCS) is a rare subtype of acute compartment syndrome (ACS), complex to diagnose and potentially fatal if left untreated. The incidence of ACS is estimated to be 7.3 per 100,000 in males and 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!